Showing results (81-90 of 110) with videos related to
Sort By:
Pageof 11
Human Movement Science|December 24, 2014
The effect of real-time auditory feedback on learning new charactersJérémy Danna, Maureen Fontaine, Vietminh Paz-Villagrán, et al.Behavior Research Methods|December 17, 2021
Synchronization of acquisition devices in neuroimaging: An application using co-registration of eye movements and electroencephalographyGelu Ionescu, Aline Frey, Nathalie Guyader, et al.Frontiers in Systems Neuroscience|December 3, 2013
Musical expertise and foreign speech perceptionEduardo Martínez-Montes, Heivet Hernández-Pérez, Julie Chobert, et al.Frontiers in Systems Neuroscience|August 23, 2013
Decision-making in information seeking on texts: an eye-fixation-related potentials investigationAline Frey, Gelu Ionescu, Benoit Lemaire, et al.Journal of Clinical Psychopharmacology|January 15, 2015
Effects of clozapine on perceptual abnormalities and sensory gating: a preliminary cross-sectional study in schizophreniaJean-Arthur Micoulaud-Franchi, Mitsuko Aramaki, Pierre Alexis Geoffroy, et al.Advances in Therapy|August 23, 2019
Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient SurveyOlivier Morand, Jack Johnson, Jerry Walter, et al.Molecular Genetics and Metabolism Reports|July 5, 2022
Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation studyChristoph Wanner, Virginia Kimonis, Juan Politei, et al.American Heart Journal|October 3, 2002
Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4)Christopher M O'Connor, Wendy A Gattis, Kirkwood F Adams, et al.Stroke|August 9, 2008
Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trialR Loch Macdonald, Neal F Kassell, Stephan Mayer, et al.Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II StudyChristopher P Denton, Éric Hachulla, Gabriela Riemekasten, et al.Pageof 11